The changing face of Clostridium difficile: What treatment options remain?

American Journal of Gastroenterology

Volumn 102, Issue 12, 2007, Pages 2789-2792

  Shen, Edie P ^a   Christina, M Surawicz ^b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; PROTON PUMP INHIBITOR; RIFAXIMIN; VANCOMYCIN;

BACTERIAL VIRULENCE; CANADA; CLOSTRIDIUM DIFFICILE; DIARRHEA; DRUG EFFICACY; ENZYME IMMUNOASSAY; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; LEUKOCYTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; METRONIDAZOLE; QUEBEC; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VANCOMYCIN;

EID: 36549016574     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01533.x     Document Type: Review

References (21)

1. McFarland LV, Beneda HW, Clarridge JE, et al. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 2007 35 : 237 53.
2. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005 26 : 273 80.
3. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. CMAJ 2004 171 : 466 72.
4. Eggertson L. C. difficile: By the numbers. CMAJ 2004 171 : 1331 2.
5. Musher DM, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005 40 : 1586 90.
6. Mohan SS, McDermott BP, Parchuri S, et al. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med 2006 119 : 356. e7 8.
7. Vasa CV, Glatt AE. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. Am J Gastroenterol 2003 98 : 354 8.
8. Peled N, Pitlik S, Samra Z, et al. Predicting Clostridium difficile toxin in hospitalized patients with antibiotic-associated diarrhea. Infect Control Hosp Epidemiol 2007 28 : 377 81.
9. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: Case series and review of the literature. Clin Infect Dis 2002 35 : 690 6.
10. Musher DM, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: Response to nitazoxanide. J Antimicrob Chemother 2007 59 : 705 10.
11. Jodlowski TZ, Oehler R, Kam LW, et al. Emerging therapies in the treatment of Clostridium difficile-associated disease. Ann Pharmacother 2006 40 : 2164 9.
12. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000 342 : 390 7.
13. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001 69 : 988 95.
14. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005 128 : 764 70.
15. McPherson S, Rees CJ, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006 49 : 640 5.
16. Juang P, Skledar SJ, Zgheib NK, et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control 2007 35 : 131 7.
17. Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care facilities: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003 52 : 1 42.
18. Boyce JM, Ligi C, Kohan C, et al. Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol 2006 27 : 479 83.
19. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 1990 88 : 137 40.
20. Hota B. Contamination, disinfection, and cross-colonization: Are hospital surfaces reservoirs for nosocomial infection? Clin Infect Dis 2004 39 : 1182 9.
21. Akerlund T, Svenungsson B, Lagergren A, et al. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006 44 : 353 8.